Italia markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
63,54-1,04 (-1,61%)
Alla chiusura: 04:00PM EST
63,50 -0,04 (-0,06%)
Dopo ore: 07:49PM EST
Accedi per pubblicare un messaggio.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Update 10 Catalysts, 3 ARE IMMINENT - No short squealing can dispute these facts.
    1. $MRK Keytruda Gps comb trial for Ovarian cancer patients, Pivotal / Binary results due to report now $ALKS rec’d Fda Fast Track for its combo
    2. $BMY Opdivo Gps for Mesothelioma patients, larger patient set, update on miracle cure patient
    3. $RHHBY Herceptin Gps Phase 2b $GLSI Twin Trial Due Now. Nct site updated in Nov w a DEC final Completion date
    4. Nps Outlicensing $250M potential Aug Ceo comment to 'stay tuned for a NPs announcement'. DEC Change of Control Filing
    5. VADIS DCIS Final Report over due A true vaccine to prevent ductal carcinoma for 65,000 US patients each year.
    6. Gps Phase 2/3 MRD+ Trial initiation/ news
    7. Aml Phase 3 Enrollment update
    8. Aml Phase 3 IDMC Statistical Efficacy analysis, possible halt for efficacy if they see a clear signal. Data 24 months on for a control group patient setting w a 5.5month os per Dr Levy in Aug, Baylor Medicals Hematologic Research Director.
    9. 3D Med $202 Milestone $$$ For the IND filed in JULY
    10. FDA Greenlight Gps for AML secondary Remission patients - 2nd half of 22 is worth about 2 b in market cap value. Cr2 is the first, initial indication, elderly patients in secondary remission median survival (21 months) 400% better than the standard treatment (5.5 months). Overall AML market expected to be approximately a billion in annual revenue. Over a Million patients with WT1 Cancer each year - GPS is a blockbuster waiting to happen.
  • s
    stephen
    $SRNE conversation
    if Bristol Myers wants to avoid downstream damages when PSS losses lawsuit to SRNE , its in their best interest to buy SRNE or partner with SRNE to avoid forever royalties damages IMHO

    the reason Aldoxorubicin was delayed, and the reason
    $SRNE
    's Cynviloq [ superior generic paclitaxel version of abraxane - in Catch n Kill lawsuit now waiting decision arbitration from 3 Judge "panel"] - this
    $CELG

    $BMY
    Non Compete Agreement stymied Aldoxorubicin's FDA Guidance with 505(b)(2) - they FDA - actually gave
    $CYTR
    the green light to file the NDA for Aldoxorubicin, but Kriegscam + Soon Shiong made a deal, that would delay Aldoxorubicin - but protect Abraxane because of patent expiration and the Non Compete - this put an extra 7 Billion dollars in
    $BMY
    's Celgene's pocket
  • j
    james
    $SLS conversation
    Dr Weber Developed Opdivo for $bmy “ Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company's lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein,"
    Jeffrey S. Weber, MD, PhD, the deputy director of the Perlmutter Cancer Center at NYU Langone Health, and chair of SELLAS Scientific Advisory Board
  • R
    Real Immuno Investor 10
    $SLS conversation
    Not if but when SLS shares are $100+ - Now is A Great Time to Invest in $SLS
    REGAL phase 3 compares Gps vs Existing SOC, Dr. Levy, Baylor Med Research Director for Hematology explained known SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing tcells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Not if, only when SLS shares trade for $100+ Jazz paid $1.5B for a lessor AML drug. $XBI beatdown is A Great Time to Invest. Dr. Levy, Baylor Med Research Director for Hematology explained AML SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing t cells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • R
    Real Immuno Investor 10
    $XBI conversation
    Not if but when SLS shares are $100+ - Now is A Great Time to Invest in $SLS
    REGAL phase 3 compares Gps vs Existing SOC, Dr. Levy, Baylor Med Research Director for Hematology explained known SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing tcells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • j
    jamboree
    $SLS conversation
    Red $XBI Green $SLS - One of the existing Partnerships are due to Announce something, its time.
    $MRK $BMY $RHHBY
  • C
    Cured
    $BMY conversation
    $BMY $SLS 25 months of Survival -so far- for sarcomatoid Mesothelioma patient with a 6 week life expectancy.
    Earlier Gps Opdivo trial halted for efficacy Journal of Clinical Oncology
    Conclusions: Administration of GPS in combination with nivo was safe, well tolerated and induced high frequency of T- and B-cell immune responses, warranting further evaluation. The 1yr PFS rate 70% compares favorably to historic rates of approximately 50% in comparable populations. Additional cohorts are planned to receive the current combination along with vaccination against additional tumor-associated antigens. Clinical trial information: NCT02737787.
    https://www.mesotheliomahope.com/blog/new-mesothelioma-treatment-galinpepimut-s-plus-nivolumab/
    Galinpepimut-S plus Nivolumab is an immunotherapy treatment used to treat mesothelioma. Learn more about this promising new drug combination.
    Galinpepimut-S plus Nivolumab is an immunotherapy treatment used to treat mesothelioma. Learn more about this promising new drug combination.
    www.mesotheliomahope.com
  • R
    Real Immuno Investor 10
    $BMY conversation
    Not if, only when SLS shares trade for $100+ Jazz paid $1.5B for a lessor AML drug. $XBI bottoming out is A Great Time to Invest. Dr. Levy, Baylor Med Research Director for Hematology explained AML SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing t cells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • j
    jim
    $XBI conversation
    Curious on the $xBI $IWC $IBB board: If a ( $SLS ) company has annual Revenue of $200M with a Projection up to $600M - and an additional billion beyond that - What is that Worth? dNPv % probabilities. However when the FDA Greenlights GPs for its first AML Indication, that is the kind of Math that becomes Certain.

    8k's re change of control in DEC too, buyout first more likely by one of the existing Partnerships $MRK $BMY $RHHBY
  • R
    Real Immuno Investor 10
    $SLS conversation
    All 3 have Partnerships with $SLS, interesting. https://www.barrons.com/articles/drug-companies-cash-product-buys-research-51641423117?tesla=y 'Other firms expected to see high swells of cash are Roche Holding ( $RHHBY ), $BMY Bristol Myers, and $MRK Merck.'

    These piles of cash shouldn’t only cheer the shareholders of big pharma firms. Smaller biotech firms will be on the receiving end of licensing or acquisition deals. When Pfizer made its deal for Arena last month, the $100 a share deal was twice Arena’s trading price.
    We searched for the largest drug companies with money to make pipeline-filling buys. Johnson & Johnson, Pfizer, and AbbVie top the list.
    We searched for the largest drug companies with money to make pipeline-filling buys. Johnson & Johnson, Pfizer, and AbbVie top the list.
    www.barrons.com
  • D
    Dude
    $SLS conversation
    Estimated Share price on News 15 is a minimum for NPS news, Gps + $Mrk + $BMY $30
  • C
    Cured
    $SLS conversation
    $bmy Ceo Received this Award the previous year 2020
    Dr. Angelos Stergiou, recipient of the Red Door Award for Advances in Cancer Research.
    https://www.newyorksocialdiary.com/opening-doors/
  • S
    Stephens
    $SLS conversation
    $GNPX Similar news to upcoming $SLS $MRK $BMY Sls has two trial results to be reported in January
    Shares of Genprex Inc. GNPX, +167.18% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration for use in combination with Merck & Co. Inc.'s MRK, +0.30% cancer treatment Keytruda. Trading volume exploded to 163.9 million shares, compared with the full-day average of about 476,600 shares, and enough to make the stock the most actively traded on major U.S. exchanges. The company said the FTD is for use in patients with histologically confirmed unresectable stage III or IV non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda.
  • G
    G Gordon Liddys’ Ghost
    I’m up over 1.1% today while the S&P 500 is down 0.33%, is it luck or just good timing? 2022 is going to be a good year for patient and wise stock pickers $RTX $XOM $BMY $JPM $VZ $DOW $PG $T $O $CPB
  • j
    jim
    $XBI conversation
    Curious on the $xBI $IWC $IBB board: If a ( $SLS ) company has annual Revenue of $200M with a Projection up to $600M - and an additional billion beyond that - What is that Worth? Mostly about dNPv % probabilities I Get. When FDA Greenlights GPs for its first AML Indication, that is the kind of Math that becomes Certain.

    8k's re change of control in DEC too, buyout first more likely by one of the existing Partnerships $MRK $BMY $RHHBY
  • E
    Ez$
    $SLS conversation
    $SLS Market Cap $85.48M? Fda greenlight in 6ish months worth $3-5B. +5 Imminent Catalysts. EZ$
    All have partnership or industry comps $JAZZ $XBI $MRKR $ADAP $AXSM
    $sls has 3 Trial Results coming in JAN $BMY $RHHBY $MRK
  • E
    Ez$
    $SLS conversation
    $SLS Market Cap $88.48M? Gps Phase 3 AML data in 6 months worth $3-5B. +5 Imminent Catalysts. EZ$
    All have partnership or industry comps $JAZZ $XBI $MRKR $ADAP $AXSM
    $sls has 3 Trial Results coming in JAN $BMY $RHHBY $MRK
  • E
    Ez$
    $SLS conversation
    $SLS Market Cap 88.323 (ridic)
    Gps Phase 3 AML data 6 months from now that could be worth $3-5B
    All have partnership or industry comps $JAZZ $XBI $MRKR $ADAP $AXSM
    $sls has 3 Trial Results coming in JAN $BMY $RHHBY $MRK
  • j
    jim
    $XBI conversation
    Curious on the $xBI $IWC $IBB board: If SLS gets a FDA Greenlight for annual Revenue of $200M with a Projection up to $600M - and an additional billion beyond that - What is that Worth?
    Big P will Pay Billions. Its Mostly about all about the dNPv % probabilities I Get. But when the FDA Greenlights GPs for its first AML Indication, that kind of Math becomes Certain and SLS will be 100$ per share, 6 ish months out.

    8k's re change of control in DEC too, buyout first more likely by one of the existing Partnerships $MRK $BMY $RHHBY